Clinical Trial Update: Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating allogeneic CD19 CAR-T cells for relapsed/refractory B-cell lymphoma including non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic CD19 CAR-T cells

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Non-hodgkin Lymphoma,B Cell | Phase 1, Phase 2 | Status: UNKNOWN